Verona Pharma Analyst Ratings
HC Wainwright & Co. : The Verona Pharma (VRNA.US) rating was confirmed and adjusted from buy to buy, with a target price of $32.00.
Verona Pharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Verona Pharma, Lowers Price Target to $30
Strategic Financing Secures Verona Pharma's Future Beyond 2026, Ensuring Buy Rating
Piper Sandler: Maintaining the Verona Pharma (VRNA.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $31.00 to $36.00.
Verona Pharma Analyst Ratings
Piper Sandler Maintains Overweight on Verona Pharma, Raises Price Target to $36
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine's Expected FDA Approval and Strong Financial Standing
Verona Pharma Analyst Ratings
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Buy Rating Affirmed: Verona Pharma's Promising Future With Ensifentrine and Expanding R&D Pipeline
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Verona Pharma (VRNA) and Molina Healthcare (MOH)
Analysts Are Bullish on Top Healthcare Stocks: Verona Pharma (VRNA), ACADIA Pharmaceuticals (ACAD)
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Verona Pharma Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Verona Pharma (VRNA)
No Data